Skip to main content
NCBI home page
PLOS One logoLink to PLOS One
. 2026 Jan 20;21(1):e0341486. doi: 10.1371/journal.pone.0341486

Correction: Impact of bictegravir/emtricitabine/tenofovir alafenamide on health-related quality of life and economic outcomes in HIV care: Substudy of the BIC-NOW clinical trial

Sergio Sequera-Arquelladas, María J Vivancos, David Vinuesa, Antonio Collado, Ignacio De Los Santos, Patricia Sorni, Noemi Cabello-Clotet, Marta Montero, Carlos Ramos Font, Alberto Terron, Maria José Galindo, Onofre Martinez, Pablo Ryan, Mohamed Omar-Mohamed, Helena Albendín-Iglesias, Rosario Javier, Alberto Romero, Coral García Vallecillos, Miguel Ángel Calleja, Carmen Hidalgo-Tenorio
PMCID: PMC12818613  PMID: 41557643

Notice of Republication

This article was republished on on January 8, 2026 to remove confidential information. Please download this article again to view the correct version.

Reference

  • 1.Sequera-Arquelladas S, Vivancos MJ, Vinuesa D, Collado A, Santos IDL, Sorni P, et al. Impact of bictegravir/emtricitabine/tenofovir alafenamide on health-related quality of life and economic outcomes in HIV care: Substudy of the BIC-NOW clinical trial. PLoS One. 2025;20(9):e0323167. doi: 10.1371/journal.pone.0323167 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from PLOS One are provided here courtesy of PLOS

RESOURCES